AAPS PharmSciTech

, Volume 10, Issue 2, pp 361–367 | Cite as

Intranasal Microemulsion of Sildenafil Citrate: In Vitro Evaluation and In Vivo Pharmacokinetic Study in Rabbits

  • Ahmed H. Elshafeey
  • Ehab R. Bendas
  • Osama H. Mohamed
Research Article

Abstract

The purpose of the present study was to prepare intranasal delivery system of sildenafil citrate and estimate its relative bioavailability after nasal administration in rabbits to attain rapid onset of action with good efficacy at lower doses. Sildenafil citrate saturated solubility was determined in different solvents, cosolvents, and microemulsion systems. For nasal application, sildenafil citrate was formulated in two different systems: the first was a cosolvent system (S3) of benzyl alcohol/ethanol/water/Transcutol/taurodeoxy cholate/Tween 20 (0.5:16.8:47.7:15.9:1:18.1% w/w). The second was a microemulsion system (ME6) containing Oleic acid: Labrasol/Transcutol/water (8.33:33.3:16.66:41.66% w/w). The prepared systems were characterized in relation to their clarity, particle size, viscosity, pH, and nasal ciliotoxicity. In vivo pharmacokinetic performance of the selected system ME6 (with no nasal ciliotoxicity) was evaluated in a group of six rabbits in a randomized crossover study and compared to the marketed oral tablets. The targeted solubility (>20 mg/ml) of sildenafil citrate was achieved with cosolvent systems S1, S3, and S5 and with microemulsion systems ME3–ME6. The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 ± 1.26 and 23.79 ± 1.16 mg/ml, respectively. Microemulsion formulation ME6 showed shorter t max (0.75 h) and higher AUC(0-∞) (1,412.42 ng h/ml) compared to the oral tablets which showed t max equals 1.25 h and AUC(0-∞) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg. The relative bioavailability was 112.89%. In conclusion, the nasal absorption of sildenafil citrate microemulsion was found to be fast, indicating the potential of nasal delivery instead of the conventional oral administration of such drug.

Key words

bioavailability intranasal microemulsion nasal sidenafil citrate solubilization 

References

  1. 1.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychological correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54–61.PubMedGoogle Scholar
  2. 2.
    Johannes CB, Araujo AB, Felman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460–3.PubMedCrossRefGoogle Scholar
  3. 3.
    NIH consensus development panel on impotence. Impotence. JAMA. 1993;270:83–90.CrossRefGoogle Scholar
  4. 4.
    Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19:67–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res. 2007;19:281–95.PubMedCrossRefGoogle Scholar
  6. 6.
    Boolell M, Allen MJ, Ballard SA. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erection dysfunction. Int J Impot Res. 1996;8:47–52.PubMedGoogle Scholar
  7. 7.
    Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43:260–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Deveci S, Peskircioglu L, Aygun C, Tekin MI, Dirim A, Ozkardes H. Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose. Int J Urol. 2004;11:989–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Richter T, Keipert S. In vitro permeation studies comparing bovine nasal mucosa, porcinecornea and artificial membrane: androstenedione in microemulsions and their components. Eur J Pharm Biopharm. 2004;58:137–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Su KSE, In “Encyclopedia of Pharmaceutical Technology”, edited by J. Swarbrick, and J. C. Baylan, Marcel Dekker, Inc. 175–201 (1993).Google Scholar
  11. 11.
    Noach A, Hurni MA, De Boer AG, Breimer DD, In Drug Absorption Enhancement. Concept, Possibilities, Limitations and Trends, Ed.: Harwood Academic Publishers: Chur, Vol. 3, 1994, p. 291–324.Google Scholar
  12. 12.
    Haecker R, Kampfe E, Mattern C. Androgenic substitution for the ageing male by nasal administration of a precursor of testosterone. Geneve: Congress: Healthy Ageing of Male, 1998.Google Scholar
  13. 13.
    Sullivan DA, Wickham LA, Rocha EM. Androgens and dry eye in So••gren’s syndrome. Ann NY Acad Sci. 1999;876:312–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Tenjarla SN. Microemulsions: An overview and pharmaceutical applications. Critical Reviews ™ in Therapeutic Drug Carrier Systems. 1999;16:461–521.Google Scholar
  15. 15.
    Lieberman HA, Rieger MM, Banker GS. Pharmaceutical dosage forms: Disperse systems, second ed, Vol 1. New York: Marcel Decker, 1996, pp. 211–281, 315–70.Google Scholar
  16. 16.
    Kovarik JM, Muller EA, Van Bree JB, Tetzloff W, Kathz K. Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83:444.PubMedCrossRefGoogle Scholar
  17. 17.
    Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Del Rev. 1998;29:89–116.CrossRefGoogle Scholar
  18. 18.
    Zaki N, Awad G, Mortadaa N, Abd ElHady S. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32:296–307.PubMedCrossRefGoogle Scholar
  19. 19.
    Hussain A, Foster T, Hirai S, Kashihara T, Batenhorst R, Jones M. Nasal absorption of propranolol in humans. J Pharm Sci. 1980;69:1240–43.PubMedGoogle Scholar
  20. 20.
    Chien YW. Nasal drug delivery systems. In: Swacrbrick J, editor. Novel drug delivery systems. New York: Marcel Dekker, 1992, pp. 139–96.Google Scholar
  21. 21.
    Knoester PD, Jonker DM, Van der Hoeven RTM, Vermeij TAC, Edelbroek PM, Brekelmans GJ, de Haan GJ. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002;53:501–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Jiang XG, Cuii JB, Fang XL, Wei Y, Xi NZ. Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharm. Sin. 1995;30:848–53.Google Scholar
  23. 23.
    Guide for the Care and Use of Laboratory Animals #86-23. Bethesda, MD: National Institutes of Health. (1985).Google Scholar
  24. 24.
    Hussain AA, Dittert LW. Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction. United States Patent. 6,200,591 (2001).Google Scholar
  25. 25.
    Smolinske SC. Handbook of food, drug, and cosmetic excipients. Boca Raton, FL. CRC Press, 1992, pp. 47–54.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Ahmed H. Elshafeey
    • 1
  • Ehab R. Bendas
    • 1
  • Osama H. Mohamed
    • 1
  1. 1.Pharmaceutics Department, College of PharmacyCairo UniversityCairoEgypt

Personalised recommendations